by MM360 Staff | Jun 6, 2025 | Myeloma News
Source: Pharmacy Times articles Panelists discuss how evolving treatment pathways at Emory Healthcare, including earlier use of emerging therapies and off-label combination treatments, are shaping the management of chronic graft-vs-host disease (cGVHD), with an...
by MM360 Staff | Jun 6, 2025 | Publications
Clin Lymphoma Myeloma Leuk. 2025 May 14:S2152-2650(25)00159-4. doi: 10.1016/j.clml.2025.05.007. Online ahead of print. ABSTRACT BACKGROUND: The standard treatment for newly diagnosed, transplant-eligible multiple myeloma (NDMM) patients typically involves triplet...
by MM360 Staff | Jun 5, 2025 | Uncategorized
Source: CureToday articles I reflect on finding peace, purpose and presence after my diagnosis through a creative writing exercise rooted in mindfulness and metaphor. Read More
by MM360 Staff | Jun 5, 2025 | Publications
BMC Cancer. 2025 Jun 4;25(1):998. doi: 10.1186/s12885-025-14420-5. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a clonal proliferative disorder of plasma cells with limited curative options. Hepatitis B (HBV) and hepatitis C (HCV) viruses have been implicated in the...
by MM360 Staff | Jun 4, 2025 | Myeloma News
Source: Pharmacy Times articles Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma. Read More
